27 Jan 2021 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt analyses December's breast cancer data, and provides an update on efti's position and outlook.e sites.
20 Jan 2021 - National Retail Association CEO Dominique Lamb discusses retail performance over the Christmas period, trends in retail, and strategies for encouraging consumer spending.
18 Jan 2021 - Tourism Accommodation Australia CEO Michael Johnson discusses the impact of COVID-19 on hotels across Australia.
15 Jan 2021 - Famed investor, author and market analyst Jim Rogers discusses the impact of the COVID-19 vaccine rollout, Chinese wine stocks, the bond bubble, why he is bullish on commodities, allegations of currency manipulation and how Aussie investors can get ahead.
12 Jan 2021 - OANDA Senior Market Analyst Craig Erlam discusses the recent Georgia Senate runoff and what control of the Senate and a Biden Presidency mean for equities; the vaccine rollout in Europe; the new Brexit deal; and the commodities market.
06 Jan 2021 - Nyrada Limited (ASX:NYR) CEO James Bonnar discusses the cholesterol-lowering market, and recent results for the company's lead drug candidate, which achieved a 57% reduction in total cholesterol.
11 Dec 2020 - Novatti Group Limited (ASX:NOV) Managing Director Peter Cook discusses the company's strategy of partnering with Tier 1 companies, including Ripple, Google Pay and Samsung Pay.
11 Dec 2020 - Cyclopharm Limited (ASX:CYC) CEO & Managing Director James McBrayer talks about USFDA approval for Technegas, the company's USA commercialisation plan, and opportunities beyond its key diagnostic market for pulmonary embolism.
10 Dec 2020 - Lepidico Limited (ASX:LPD) Managing Director Joe Walsh discusses the company's strategic collaboration and technology licence agreement with Cornish Lithium, permitting for its plant in Abu Dhabi, and interest in its critical minerals from the United States International Development Finance Corporation.
09 Dec 2020 - Alterity Therapeutics Limited (ASX:ATH) Chairman and CEO Geoffrey Kempler provides an update on the company's lead compound ATH434 for Multiple System Atrophy, its dual strategy in Europe and the US and its Phase 2 plans.
